Clinical questions to be addressed in clinical trials.
| Abbreviations: BMT, bone marrow transplant; IFN, interferon; ABMT, allogeneic BMT; DLI, donor lymphocye infusions; Ara-C, cytarabine | |
| Frontline treatment | Phase III study ongoing |
| Combination | Feasibility of combination with IFN or Peg-IFN |
| Feasibility of combination with low-dose Ara-C | |
| Feasibility of combination with chemotherapy | |
| BMT | Safety of BMT after STI571 therapy |
| Feasibility of prophylactic treatment after BMT | |
| Treatment of relapses post-BMT | |
| Feasibility of combination with DLI | |
| ABMT | In vivo purging |
| Maintenance therapy after ABMT | |
| Abbreviations: BMT, bone marrow transplant; IFN, interferon; ABMT, allogeneic BMT; DLI, donor lymphocye infusions; Ara-C, cytarabine | |
| Frontline treatment | Phase III study ongoing |
| Combination | Feasibility of combination with IFN or Peg-IFN |
| Feasibility of combination with low-dose Ara-C | |
| Feasibility of combination with chemotherapy | |
| BMT | Safety of BMT after STI571 therapy |
| Feasibility of prophylactic treatment after BMT | |
| Treatment of relapses post-BMT | |
| Feasibility of combination with DLI | |
| ABMT | In vivo purging |
| Maintenance therapy after ABMT | |